Would you use first line combination immunotherapy with chemotherapy in patients with metastatic low ER/PR+ (<10%), HER2 negative breast cancer?

Given that trials excluded patients with low ER, PR for this approach.

Answer from: Medical Oncologist at Academic Institution

Low positive with 1% to 10% cells staining for ER are particularly clinically challenging, although uncommon (accounting for 2%-3% of ER-positive cancers). The first step is to make sure the IHC testing algorithm relies on accurate, reproducible assays, and clinically validated methods. Up to 20% of...

Comments

Medical Oncologist at Rutgers Cancer Institute of New Jersey
Have you been able to obtain Pd-1 scores on these ...

Medical Oncologist at University of North Carolina at Chapel Hill
Yes, we’ve had a few cases where we were abl...

Please select the option that best describes you:

Would you use first line combination immunotherapy with chemotherapy in patients with metastatic low ER/PR+ (<10%), HER2 negative breast cancer?

Related Questions